JPWO2023009572A5 - - Google Patents
Info
- Publication number
- JPWO2023009572A5 JPWO2023009572A5 JP2024505230A JP2024505230A JPWO2023009572A5 JP WO2023009572 A5 JPWO2023009572 A5 JP WO2023009572A5 JP 2024505230 A JP2024505230 A JP 2024505230A JP 2024505230 A JP2024505230 A JP 2024505230A JP WO2023009572 A5 JPWO2023009572 A5 JP WO2023009572A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- combination
- raf
- administered
- kras
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163203555P | 2021-07-27 | 2021-07-27 | |
| US63/203,555 | 2021-07-27 | ||
| PCT/US2022/038434 WO2023009572A1 (en) | 2021-07-27 | 2022-07-27 | Combination therapy for treating abnormal cell growth |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024528039A JP2024528039A (ja) | 2024-07-26 |
| JPWO2023009572A5 true JPWO2023009572A5 (https=) | 2025-08-04 |
| JP2024528039A5 JP2024528039A5 (https=) | 2025-08-04 |
Family
ID=85087234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024505230A Pending JP2024528039A (ja) | 2021-07-27 | 2022-07-27 | 異常な細胞成長を処置するための組み合わせ治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250049792A1 (https=) |
| EP (1) | EP4376828A4 (https=) |
| JP (1) | JP2024528039A (https=) |
| KR (1) | KR20240041978A (https=) |
| CN (1) | CN118103040A (https=) |
| AU (1) | AU2022318885A1 (https=) |
| CA (1) | CA3227498A1 (https=) |
| IL (1) | IL310477A (https=) |
| MX (1) | MX2024001248A (https=) |
| WO (1) | WO2023009572A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7582694B2 (ja) | 2020-01-10 | 2024-11-13 | イミューニヤリング コーポレーション | Ｍｅｋ阻害剤及びその治療的使用 |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| CN119947725A (zh) * | 2022-09-30 | 2025-05-06 | 应世生物科技(南京)有限公司 | Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途 |
| WO2024173761A1 (en) * | 2023-02-17 | 2024-08-22 | Ikena Oncology, Inc. | Combinations comprising mek inhibitors for use in the treatment of cancer |
| CN121263418A (zh) | 2023-04-07 | 2026-01-02 | 锐新医药公司 | 大环ras抑制剂 |
| KR20260005904A (ko) | 2023-04-07 | 2026-01-12 | 레볼루션 메디슨즈, 인크. | 매크로사이클릭 ras 억제제 |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| AU2024265078A1 (en) * | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016115376A1 (en) * | 2015-01-14 | 2016-07-21 | The Regents Of The University Of California | Detection and treatment of double drug resistant melanomas |
| WO2021047783A1 (en) * | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
| JP7582694B2 (ja) * | 2020-01-10 | 2024-11-13 | イミューニヤリング コーポレーション | Ｍｅｋ阻害剤及びその治療的使用 |
-
2022
- 2022-07-27 EP EP22850215.9A patent/EP4376828A4/en active Pending
- 2022-07-27 MX MX2024001248A patent/MX2024001248A/es unknown
- 2022-07-27 IL IL310477A patent/IL310477A/en unknown
- 2022-07-27 CN CN202280063475.8A patent/CN118103040A/zh active Pending
- 2022-07-27 US US18/292,086 patent/US20250049792A1/en active Pending
- 2022-07-27 JP JP2024505230A patent/JP2024528039A/ja active Pending
- 2022-07-27 AU AU2022318885A patent/AU2022318885A1/en active Pending
- 2022-07-27 WO PCT/US2022/038434 patent/WO2023009572A1/en not_active Ceased
- 2022-07-27 KR KR1020247006593A patent/KR20240041978A/ko active Pending
- 2022-07-27 CA CA3227498A patent/CA3227498A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Niu et al. | Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC | |
| Gbolahan et al. | A phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma | |
| JPWO2022015736A5 (https=) | ||
| Kitayama | Intraperitoneal chemotherapy against peritoneal carcinomatosis: current status and future perspective | |
| Mukkamalla et al. | Gastric cancer | |
| JPWO2023009572A5 (https=) | ||
| JP2020514311A5 (https=) | ||
| JP2018508593A5 (https=) | ||
| JP2017505321A5 (https=) | ||
| JPWO2021154929A5 (https=) | ||
| Uncu et al. | Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients | |
| TWI726133B (zh) | 基於癌細胞之代謝特異性之新穎抗惡性腫瘤劑 | |
| Chi et al. | Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer | |
| Wu et al. | Effect of cetuximab combined with chemotherapy in treating metastatic colorectal cancer and its prognostic analysis | |
| Li et al. | Excessive vitamin B6 during treatment is related to poor prognosis of patients with nasopharyngeal carcinoma: A U-shaped distribution suggests low dose supplement | |
| Morise et al. | Patient with advanced intrahepatic cholangiocarcinoma with long-term survival successfully treated with a combination of surgery and chemotherapy | |
| Fukuda et al. | Real-world outcomes of trifluridine/tipiracil for heavily pretreated patients with advanced gastric cancer | |
| CA3151395A1 (en) | Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings | |
| JPWO2023004308A5 (https=) | ||
| Yeo et al. | Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors | |
| JPWO2019144098A5 (https=) | ||
| Shiraishi et al. | P42-7 FOLFOX-based chemoradiotherapy for locally advanced/metastatic esophageal squamous cell carcinoma with severe dysphagia | |
| Iede | P43-7 Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer | |
| JPWO2023278860A5 (https=) | ||
| Saglam et al. | A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinoma |